Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N C P Cross

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Leukemia|July 3, 2002
Tyrosine kinase fusion genes in chronic myeloproliferative diseasesN C P Cross, A Reiter
Cellular and Molecular Life Sciences : CMLS|December 8, 2004
Oncogenic derivatives of platelet-derived growth factor receptorsA V Jones, N C P Cross
Acta Haematologica|March 29, 2002
The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1D Macdonald, A Reiter, N C P Cross
Best Practice & Research. Clinical Haematology|June 20, 2006
Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapyJason Gotlib, N C P Cross, D Gary Gilliland
Leukemia|June 6, 2008
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disordersC Walz, N C P Cross, R A Van Etten, et al.
Leukemia|April 17, 2012
Standardized definitions of molecular response in chronic myeloid leukemiaN C P Cross, H E White, M C Müller, et al.
Leukemia|March 19, 2004
Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074E K Grand, A J Chase, C Heath, et al.
Leukemia|February 25, 2006
Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophiliaJ Score, C Curtis, K Waghorn, et al.
Lancet (London, England)|August 23, 2003
Imatinib for systemic mast-cell diseaseA Pardanani, M Elliott, T Reeder, et al.
Leukemia|September 23, 2006
Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemiaS Branford, N C P Cross, A Hochhaus, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Leukemia|July 3, 2002
Tyrosine kinase fusion genes in chronic myeloproliferative diseasesN C P Cross, A Reiter
Cellular and Molecular Life Sciences : CMLS|December 8, 2004
Oncogenic derivatives of platelet-derived growth factor receptorsA V Jones, N C P Cross
Acta Haematologica|March 29, 2002
The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1D Macdonald, A Reiter, N C P Cross
Best Practice & Research. Clinical Haematology|June 20, 2006
Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapyJason Gotlib, N C P Cross, D Gary Gilliland
Leukemia|June 6, 2008
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disordersC Walz, N C P Cross, R A Van Etten, et al.
Leukemia|April 17, 2012
Standardized definitions of molecular response in chronic myeloid leukemiaN C P Cross, H E White, M C Müller, et al.
Leukemia|March 19, 2004
Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074E K Grand, A J Chase, C Heath, et al.
Leukemia|February 25, 2006
Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophiliaJ Score, C Curtis, K Waghorn, et al.
Lancet (London, England)|August 23, 2003
Imatinib for systemic mast-cell diseaseA Pardanani, M Elliott, T Reeder, et al.
Leukemia|September 23, 2006
Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemiaS Branford, N C P Cross, A Hochhaus, et al.
Pageof 5